Transcript
There has been an important first step in finding a safe and effective vaccine for covid-19.
A participant in a coronavirus vaccine trial in the US has been administered their first dose.
The National Institute of Allergy and Infectious Diseases is funding the trial and made the announcement Monday.
The trial is run out of the Kaiser Permanente Washington Health Research Institute in Seattle.
The study aims to enroll a total of 45 healthy adults over a six week time frame.
Each participant will receive two injections about a month apart in varying doses.
The study is meant to prove that the vaccine is safe and to induce a desired response from participants immune systems.
However experts say proving the vaccine is effective in preventing covid-19 infection will require follow-up studies involving many more participants.
And that could take many more months.
Posted – 3.17.20